Skip to main content
Equibles

CHARLES SCHWAB INVESTMENT MANAGEMENT INC

Position in NVCT — Nuvectis Pharma, Inc.

CIK 884546 SAN FRANCISCO, CA
Back to NVCT Full portfolio

Position in NVCT

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$1,050,675
+$666,920 QoQ
Shares Held
57,133
+15.1% QoQ
Ownership
0.175%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#23
of 82 holders
Holding Since
Jun 2023
9 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in NVCT Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

CHARLES SCHWAB INVESTMENT MANAGEMENT INC holds $7,402,603,842 across 299 Biotechnology names. NVCT ranks #221 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 2,041,282 $1,013,966,007
2 REGN
Regeneron Pharmaceuticals, Inc.
 846,306 $527,705,642
3 RVMD
Revolution Medicines, Inc.
 1,917,025 $359,020,441
4 MRNA
Moderna, Inc.
 4,838,884 $338,867,045
5 ALNY
Alnylam Pharmaceuticals, Inc.
 755,377 $227,391,137
6 INCY
Incyte Corp
 1,692,439 $191,854,884
7 RPRX
Royalty Pharma plc
 3,083,528 $172,893,414
8 CYTK
Cytokinetics Inc
 1,565,781 $133,388,883

All Filings in NVCT

Export CSV
9 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $1,050,675 57,133
2026-03-31 $383,755 49,645
2025-12-31 $332,366 44,022
2025-09-30 $228,651 37,982
2025-06-30 $283,725 37,982
2024-03-31 $163,344 19,920
2023-12-31 $166,132 19,920
2023-09-30 $256,768 19,920
2023-06-30 $287,380 17,995